No Data
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet
Design Therapeutics: A Cautious Hold Amidst Financial Stability and Clinical Progress
Design Therapeutics Price Target Maintained With a $4.00/Share by RBC Capital
Design Therapeutics Analyst Ratings
RBC Capital Sticks to Their Hold Rating for Design Therapeutics (DSGN)
Express News | Design Therapeutics Inc : Leerink Partners Raises Target Price to $5.00 From $4.00